Augmedix, Inc.
AUGX · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.35 | -0.11 | -0.99 | 0.09 |
| FCF Yield | -7.21% | -31.15% | -21.08% | -11.47% |
| EV / EBITDA | -13.38 | -2.57 | -4.44 | -9.78 |
| Quality | ||||
| ROIC | -37.04% | -80.06% | -37.31% | -71.55% |
| Gross Margin | 47.99% | 45.11% | 45.15% | 41.22% |
| Cash Conversion Ratio | 0.81 | 0.69 | 1.04 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | 26.49% | 23.35% | 16.25% | 15.08% |
| Free Cash Flow Growth | -2.01% | 5.32% | -27.63% | 2.73% |
| Safety | ||||
| Net Debt / EBITDA | 1.16 | 0.10 | 1.85 | 0.45 |
| Interest Coverage | -8.34 | -13.36 | -7.97 | -9.42 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -8.73 | -6.51 | 4.38 |
| Cash Conversion Cycle | 58.47 | -0.44 | 21.14 | 133.17 |